Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #4 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
3 of 4 strong
The short version
Target revenue of INR 2,500 to 3,000 crores within 3-4 years. Senores Pharmaceuticals guides for a 50% PAT growth in FY27, with expectations for growth to continue thereafter, though exact FY28 numbers are premature to specify.
From Senores Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Target revenue of INR 2,500 to 3,000 crores within 3-4 years.
- FY '27 guidance: 30%-40% revenue growth; 50%-60% PAT growth.
- Similar growth trajectory expected post FY '27, though exact FY '28 guidance is premature.
- Growth driven by:
- Regulated markets: US ANDA portfolio expanding from 30 to 58 approved ANDAs; 23 commercialized; 35 more to launch in 18-20 months.
- Emerging markets: 500+ current product approvals; 900+ registrations in pipeline.
- India branded generics: expected to reach INR 50-60 crores sales with 35%-40% EBITDA.
- Production capacity expansion at Apnar and US facilities to support growth.
2 more points from Senores Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 Capex planned: INR 100-120 crores across subsidiaries, mainly for capacity expansion in oral solids and starting an injectable pilot plant.
- Apnar facility: Expanding with third and fourth production lines to ramp up oral solid manufacturing capacity.
- US plant capacities are also being increased to support regulated market growth.
- Sterile injectable project: Scaled down to a pilot facility with lower cost; full-scale execution pushed to H2 FY27 pending shareholder approval.
2 more points from Senores Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Senores Pharmaceuticals has about 58 approved ANDAs, with 35 approved but yet to be launched.
- There are 39 more ANDAs (molecules) under development, some filed, some to be filed.
- The emerging markets segment has around 500 approved product registrations.
- Additionally, about 900 product registrations are currently in the pipeline, already filed with respective Ministries of Health.
2 more points from Senores Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Senores Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹192 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharma.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Senores Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Senores Pharmaceuticals Ltd Q1 FY27 results?
Target revenue of INR 2,500 to 3,000 crores within 3-4 years. Senores Pharmaceuticals guides for a 50% PAT growth in FY27, with expectations for growth to continue thereafter, though exact FY28 numbers are premature to specify.
What is Senores Pharmaceuticals Ltd share price analysis?
Senores Pharmaceuticals Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 48.0 with a market cap of ₹6,071 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharmaceuticals Ltd planning capital expenditure?
FY27 Capex planned: INR 100-120 crores across subsidiaries, mainly for capacity expansion in oral solids and starting an injectable pilot plant.
Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.